Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
IPO Year: 2022
Exchange: NASDAQ
Website: https://sharpstechnology.com
SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)
SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)
SC 13G - Sharps Technology Inc. (0001737995) (Subject)
SC 13G - Sharps Technology Inc. (0001737995) (Subject)
SCHEDULE 13G - Sharps Technology Inc. (0001737995) (Subject)
8-K - Sharps Technology Inc. (0001737995) (Filer)
8-K - Sharps Technology Inc. (0001737995) (Filer)
8-K - Sharps Technology Inc. (0001737995) (Filer)
8-K - Sharps Technology Inc. (0001737995) (Filer)
8-K - Sharps Technology Inc. (0001737995) (Filer)
8-K - Sharps Technology Inc. (0001737995) (Filer)
10-K/A - Sharps Technology Inc. (0001737995) (Filer)
8-K - Sharps Technology Inc. (0001737995) (Filer)
8-K - Sharps Technology Inc. (0001737995) (Filer)
Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces the receipt of a $100,000 purchase order from a Hungarian vaccine provider. This order supports the recently announced $400,000 SoloGard™ order, which is part o
Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreementInvestments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long-term contract demand NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the receipt of a $400,000 purchase order from a U.S. leader in IV flushing solutions. This marks the first order under the previously announ
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced that it will effect a 1-for-300 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on April 27, 2025 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Sharps has requested that its Common Stock begin trading on April 28, 2025, on a post-reverse split basis on the Nasdaq under th
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ:STSS) (the "Company" or "Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company's proposal before the shareholder meeting, which is scheduled to be held on March 28, 2025, at 10:00 a.m. Eastern Time. Voting 'FOR' the reverse stock split of the Company's common stock is imperative for Sharps to maintain compliance with Nasdaq's minimum bid price requirement and ensure that the Company's common stock remains listed on Nasdaq and is not delisted to the OTC Markets. If you re
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, As we reflect on the progress since our December update, I am excited to share the latest developments that will shape our Company's trajectory in 2025 and beyond. With the successful closing of a $20 million financing in January, we strengthened our balance sheet by securing working capital for operating and capital expenditures and paid down our debt to zero. We believe that we are now well-positioned to advance our operations in Hungary through the previously announced SoloGard and SecureGard agreements, alongside ongoing business development initiatives in the U.S. We remain fully committed to driving revenue
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ:STSS) (the "Company"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offering closed on January 29, 2025. The offering consisted of 14,285,714 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant, (ii) one (1) Series A Register
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ:STSS) (the "Company"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $20.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering consists of 14,285,714 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant, (ii) one (1) Series A Registered Common Warrant to purchase one (1) sha
Shareholder letter includes details about the $50+ million sales agreement with a US-based pharma company, plans for Hungary SoloGard manufacturing expansion, and expected delivery scheduleInitial production and commercial deliveries to begin in Q1 2025 Sales team has signed an agreement to sell and deliver current SecureGard 1mL and 3mL inventory, with shipments and revenue that began in early December NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, issues a shareholder letter from Robert Hayes, the Company's Chief Exe
Signed multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early DecemberAgreements also include new forecasted orders and commitments for all current SecureGard capacity, to begin in Q2 2025The SecureGard agreements will strengthen the potential revenue curve for the Hungary Operation starting in 2024 NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, has begun deliveries of its 1mL and 3mL SecureGard safety syringes under the new sales agreements with a promin
NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market ("Nasdaq") that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024. The Company's Chief Executive Officer Robert Hayes stated, "We are extremely pleased with our bid price compliance. We view our listing on Nasdaq
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4/A - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4/A - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
4 - Sharps Technology Inc. (0001737995) (Issuer)
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B
ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip
New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list
ORLANDO, FL / ACCESSWIRE / May 19, 2023 / RedChip Companies will air new interviews with Sharps Technology, Inc. (NASDAQ:STSS, STSSW))) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) on The RedChip Money Report® on Bloomberg TV, this Saturday, May 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology, Inc.: https://www.stssinfo.com/interview_accessBullFrog AI Holdings, Inc.: https://bfrginfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' ex
ORLANDO, FL / ACCESSWIRE / April 5, 2023 / RedChip Companies will air new interviews with BullFrog AI (NASDAQ:BFRG) and Sharps Technology (NASDAQ:STSS) on The RedChip Money Report® on Bloomberg TV, this Saturday, April 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI (NASDAQ:BFRG): https://bfrginfo.com/interview_accessSharps Technology (NASDAQ:STSS): https://www.stssinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discoverin
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru
Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl